US OptionsDetailed Quotes
MYGN250117C11000
- 0.00
- 0.000.00%
15min DelayTrading Jan 6 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest11.00Strike Price0.00Turnover178.05%IV-20.17%PremiumJan 17, 2025Expiry Date2.78Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8143Delta0.0621Gamma4.34Leverage Ratio-0.0531Theta0.0024Rho3.53Eff Leverage0.0065Vega
Myriad Genetics Stock Discussion
Sign in to post a comment
$Myriad Genetics (MYGN.US)$ what happen to this stock?
1
1
$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE
1
14
The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.
Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.
The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.
The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.
Though Myriad Genetics maintains a cash surplus, doubt arises from its lack of free cash flow, negative EBIT, and significant liabilities.
CEO Paul Diaz is confident in Raha's capability to enhance profitability and expand the company, leveraging his substantial experience in diagnostics. Diaz considers Raha will introduce new ideas and expertise to progress current business missions and operational excellence.
Goldman Sachs were very encouraged by the presentation and lab tour at the Investor Day. While the stock could benefit from a clean quarter where the improved organic growth profile is highlighted, the market should be ascribing more credit to the transformation in the business over the past few years. Goldman see an improving financial profile as previous investments in commercial, revenue cycle management, lab automation and R&D contribute to growth...
+2
$Amesite (AMST.US)$ $Ascendis Pharma A/S (ASND.US)$ $AST SpaceMobile (ASTS.US)$ $Butterfly Network (BFLY.US)$ $Guardforce AI (GFAI.US)$ $Alphabet-C (GOOG.US)$ $Hitek Global (HKIT.US)$ $Indonesia Energy (INDO.US)$ $Nordstrom (JWN.US)$ $Myriad Genetics (MYGN.US)$ $NICE Ltd (NICE.US)$ $OncoSec Medical (ONCS.US)$ $Palisade Bio (PALI.US)$ $Cryptyde (TYDE.US)$ $21Vianet (VNET.US)$
2
No comment yet
905745367 OP : It will bounce back